J

Johnson & Johnson

Makes prescription drugs and medical devices

Regulatory Affairs Manager - Biomaterials External Innovation

Full-TimeUpdated Deadline 11/4/26
$117k - $201.3k+ Long-term incentive program
Senior, Expert
Bachelor's, Master's
West Chester, PA, USA+1 moreMore locations: Raynham, MA, USA
HybridHybrid work in Raynham, MA or West Chester, PA.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a scientific, engineering, pharmacy, or other relevant technical discipline is required; an advanced degree is preferred.
  • At least 8 years of relevant experience in the medical device, biologics, pharmaceutical, combination-product, or other regulated healthcare industry, including demonstrated experience supporting complex product development programs.
  • Demonstrated specialized regulatory expertise in Chemistry, Manufacturing, and Controls (CMC) and Current Good Manufacturing Practice (CGMP) requirements.
  • Experience developing and executing regulatory strategies aligned with business objectives.
  • Expertise in biologics, biomaterials, combination products, CMC, CGMP, Biologics License Applications (BLA), and Investigational Device Exemptions (IDE) requirements.
  • Ability to communicate clearly in writing and verbally.
Responsibilities
  • Lead regulatory activities supporting development, submission, approval, and lifecycle management of biomaterials, biologics, combination products, and medical devices before global regulatory authorities; develop risk-based strategies for timely development and commercialization.
  • Manage assigned Regulatory Affairs activities, set strategic priorities, and communicate regulatory objectives, risks, and recommendations to project teams and business leaders.
  • Lead preparation and maintenance of regulatory submissions and files, including BLAs, IDEs and IDE Supplements, PMAs and PMA Supplements, 510(k)s, De Novo requests, HDEs, annual reports, global change notifications, and technical documentation as applicable to the assigned portfolio.
  • Define and execute regulatory strategies for pipeline development, clinical programs, and global launch readiness, especially for Biomaterials External Innovation opportunities.
  • Partner with R&D, Quality, Clinical, Medical Affairs, Supply Chain, Commercial, Business Development, and other cross-functional stakeholders to evaluate opportunities and implement regulatory strategies.
  • Exercise independent judgment on complex regulatory issues, identify key risks and evidence requirements, and drive regulatory deliverables across assigned projects and external partnerships.
  • Provide day-to-day leadership, coaching, and technical guidance to Regulatory Affairs colleagues and cross-functional project teams, as applicable.
  • Develop and deliver training for cross-functional partners on current and emerging regulatory, CMC, CGMP, biologics, combination-product, and clinical investigation requirements.
  • Ensure aligned and coordinated contact and communication with global and regional/local regulatory agencies.
  • Ensure company policies, procedures, and practices comply with appropriate regulatory requirements.
  • Support timely regulatory approvals and clearances for assigned programs; identify capability gaps, propose solutions, and implement plans aligned with organizational and Regulatory Affairs objectives.
  • Communicate a clear regulatory vision and foster accountability, collaboration, and effective execution across internal teams and external partners.
  • Lead Regulatory Affairs screening and technical due diligence for Biomaterials External Innovation, external partnerships, licensing, acquisition, and other business development opportunities; develop early-stage regulatory assessments, identify critical risks and evidence needs, and recommend viable development pathways.
  • Represent the Biomaterials External Innovation regulatory perspective in internal governance forums, partner interactions, diligence activities, and regulatory agency engagements.
  • Cultivate external relationships with regulators in key markets and collaborate internally with regional, policy, EU strategy, R&D, Medical Affairs, Clinical Affairs, GSM, and other partners.
  • Anticipate and influence regulatory changes in key markets to maximize patient access to innovative technologies.
  • Provide clear direction, technical expertise, and constructive feedback to regulatory colleagues, project teams, and external partners.
  • Coordinate accountable cross-functional teams and external partners to achieve timely, high-quality regulatory outcomes while balancing strategic and near-term priorities.
  • Apply specialized scientific and regulatory expertise to guide development planning, risk mitigation, submissions, and lifecycle activities in applicable markets.
  • Educate and coach others on developing and executing business plans and Regulatory Affairs strategies.
  • Advise and challenge cross-functional business partners to support sound business decisions; make and stand behind complex decisions in ambiguous situations with significant potential organizational impact.
Desired Qualifications
  • Direct experience with BLA and IDE development, submission, or lifecycle support is strongly preferred.
  • Experience assessing early-stage external innovation, conducting regulatory due diligence, and supporting external partnerships or business development opportunities is strongly preferred.
  • Preferred areas include biomaterials, regenerative medicine, external partnerships, business development, global regulatory strategy, PMA, De Novo, 510(k), technical documentation, compliance risk, fact-based decision-making, continuous improvement, developing others, inclusive leadership, innovation, and strategic thinking.
  • An advanced degree is preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.